HFMA Australia

hfma.org.au

At HFMA we strive to create a sustainable healthcare for a healthy Australia. Our mission is to connect and build capacity and capability in Australian health finance professionals in order for them to become leaders in the Health Industry. Our Strategic Plan will see many progressions into the future, as we take on new events and projects to allow our member benefits to grow.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

LEGEND BIOTECH ANNOUNCES EXTENSION OF PDUFA DATE FOR CILTA-CEL

Cilta-cel | November 01, 2021

news image

Legend Biotech Corporation (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) target date for ciltacabtagene autoleucel (cilta-cel) to February 28, 2022. Cilta-cel is a BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy being investigated for the treatment of adults with relapsed and/or refractory multiple myelo...

Read More

MEDICAL

NIKANG THERAPEUTICS COMPLETES $200 MILLION SERIES C FINANCING TO ADVANCE HIGHLY DIFFERENTIATED SMALL MOLECULES ADDRESSING DIFFICULT-TO-DRUG TARGETS

NiKang Therapeutics | May 31, 2021

news image

NiKang Therapeutics Inc., a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to assist patients with unmet medical needs; today announced the completion of an oversubscribed $200 million Series C financing led by Cormorant Asset Management, HBM Healthcare Investments, and Octagon Capital Advisors with participation from a premier syndicate of funds, including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Grou...

Read More

CDI LABS ANNOUNCES THE ADDITION OF ITS SARS-COV-2 (COVID19) ASSAY PLATFORM

PR Newswire | August 21, 2020

news image

CDI Laboratories, Inc. announced the addition of its SARS-CoV-2 (COVID19) assay platform. The assays use CDI's VirScan service which can detect antibodies to 1345 individual viral strains representing species from 76 viral genera. This is coupled with CDI's 2 in 1 SARS-CoV-2 antigen microarray which contains overlapping SARS-CoV-2 peptides as well as full-length proteins. This will allow researchers, therapeutic developers, and vaccine developers, to analyze human serum for all kno...

Read More

ORI BIOTECH RAISES $30 MILLION $30 MILLION SERIES A FINANCING ROUND TO ADVANCE INNOVATION IN CELL AND GENE THERAPY MANUFACTURING

Ori Biotech | October 15, 2020

news image

Ori Biotech Ltd (Ori), a leading innovator in cell and gene therapy (CGT) manufacturing, today announced the successful close of a $30 million Series A financing round, bringing the company's total funding to date to $41 million. The new funding will be used to help bring Ori's innovative manufacturing platform to the market. The Ori platform delivers scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers. The Series A investor s...

Read More
news image

INDUSTRIAL IMPACT

LEGEND BIOTECH ANNOUNCES EXTENSION OF PDUFA DATE FOR CILTA-CEL

Cilta-cel | November 01, 2021

Legend Biotech Corporation (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) target date for ciltacabtagene autoleucel (cilta-cel) to February 28, 2022. Cilta-cel is a BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy being investigated for the treatment of adults with relapsed and/or refractory multiple myelo...

Read More
news image

MEDICAL

NIKANG THERAPEUTICS COMPLETES $200 MILLION SERIES C FINANCING TO ADVANCE HIGHLY DIFFERENTIATED SMALL MOLECULES ADDRESSING DIFFICULT-TO-DRUG TARGETS

NiKang Therapeutics | May 31, 2021

NiKang Therapeutics Inc., a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to assist patients with unmet medical needs; today announced the completion of an oversubscribed $200 million Series C financing led by Cormorant Asset Management, HBM Healthcare Investments, and Octagon Capital Advisors with participation from a premier syndicate of funds, including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Grou...

Read More
news image

CDI LABS ANNOUNCES THE ADDITION OF ITS SARS-COV-2 (COVID19) ASSAY PLATFORM

PR Newswire | August 21, 2020

CDI Laboratories, Inc. announced the addition of its SARS-CoV-2 (COVID19) assay platform. The assays use CDI's VirScan service which can detect antibodies to 1345 individual viral strains representing species from 76 viral genera. This is coupled with CDI's 2 in 1 SARS-CoV-2 antigen microarray which contains overlapping SARS-CoV-2 peptides as well as full-length proteins. This will allow researchers, therapeutic developers, and vaccine developers, to analyze human serum for all kno...

Read More
news image

ORI BIOTECH RAISES $30 MILLION $30 MILLION SERIES A FINANCING ROUND TO ADVANCE INNOVATION IN CELL AND GENE THERAPY MANUFACTURING

Ori Biotech | October 15, 2020

Ori Biotech Ltd (Ori), a leading innovator in cell and gene therapy (CGT) manufacturing, today announced the successful close of a $30 million Series A financing round, bringing the company's total funding to date to $41 million. The new funding will be used to help bring Ori's innovative manufacturing platform to the market. The Ori platform delivers scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers. The Series A investor s...

Read More